1994 Volume 42 Issue Supplement4 Pages 468-476
Clinical studies were carr+ied out to assess the effect and safety of biapenem (BIPM) in urogenital field infections, and the results were as follows.
In the laboratory study, the MIC50 of BIPM against 77 clinical strains of Pseudornonas aeruginosa isolated from c-UTI in 1992/1993 was 1.56μg/ml, which was lower for 2 tubes than imipenem.
In the clinical study, thirty-nine patients, including 28 cases of chronic complicated UTI, 3 of acute uncomplicated pyelonephritis and 8 of acute bacterial prostatitis, were treated at doses of 300-1200mg a day for 2-10 days. In complicated UTI, the clinical efficacy was excellent or moderate in 19 of 21 patients (90%). For the bacteriological response, in 19 strains of 8 species of GPC, and 17 strains of 8 species of GNB, 94% of bacteria were eradicated after treatment. In uncomplicated UTI and acute bacterial prostatitis, the clinical efficacy was 100%. No side effects were observed. In abnormal laboratory findings, mild transient elevation of GPT in 3 cases and decrease of leucocytes in 1 case were observed.
